Patrick Burnett insider trades: Arcutis Biotherapeutics (ARQT) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Patrick reports to the SEC
Open-market buys and sales
36 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | ARQT | ↓ Sell | 943 | $31.86 | $30K | Direct | Nov 4, 2026 (2d) |
| Aug 19, 2026 | ARQT | ↓ Sell | 1,697 | $27.00 | $46K | Direct | Aug 21, 2026 (2d) |
| Aug 12, 2026 | ARQT | ↓ Sell | 15,000 | $26.33 | $395K | Direct | Aug 13, 2026 (1d) |
| Aug 3, 2026 | ARQT | ↓ Sell | 955 | $26.12 | $25K | Direct | Aug 5, 2026 (2d) |
| May 11, 2026 | ARQT | ↓ Sell | 222 | $21.05 | $5K | Direct | May 13, 2026 (2d) |
| May 4, 2026 | ARQT | ↓ Sell | 684 | $23.61 | $16K | Direct | May 6, 2026 (2d) |
| Feb 4, 2026 | ARQT | ↓ Sell | 13,469 | $25.72 | $346K | Direct | Feb 4, 2026 (0d) |
| Jan 5, 2026 | ARQT | ↓ Sell | 2,490 | $28.98 | $72K | Direct | Jan 7, 2026 (2d) |
| Dec 31, 2025 | ARQT | ↓ Sell | 1,697 | $29.20 | $50K | Direct | Jan 2, 2026 (2d) |
| Dec 15, 2025 | ARQT | ↓ Sell | 11,500 | $28.94 | $333K | Direct | Dec 17, 2025 (2d) |
| Nov 6, 2025 | ARQT | ↓ Sell | 17,250 | $24.18 | $417K | Direct | Nov 10, 2025 (4d) |
| Nov 5, 2025 | ARQT | ↓ Sell | 6,486 | $24.12 | $156K | Direct | Nov 5, 2025 (0d) |
| Aug 21, 2025 | ARQT | ↓ Sell10b5-1 | 4,188 | $15.82 | $66K | Direct | Aug 21, 2025 (0d) |
| Aug 8, 2025 | ARQT | ↓ Sell10b5-1 | 3,847 | $14.03 | $54K | Direct | Aug 12, 2025 (4d) |
| Aug 4, 2025 | ARQT | ↓ Sell | 2,622 | $14.33 | $38K | Direct | Aug 5, 2025 (1d) |
| Jul 14, 2025 | ARQT | ↓ Sell | 28,750 | $15.05 | $433K | Direct | Jul 14, 2025 (0d) |
| May 8, 2025 | ARQT | ↓ Sell10b5-1 | 3,871 | $13.59 | $53K | Direct | May 9, 2025 (1d) |
| May 2, 2025 | ARQT | ↓ Sell | 2,597 | $15.19 | $39K | Direct | May 5, 2025 (3d) |
| Mar 14, 2025 | ARQT | ↓ Sell10b5-1 | 61,403 | $14.99 | $921K | Direct | Mar 17, 2025 (3d) |
| Mar 4, 2025 | ARQT | ↓ Sell | 3,773 | $13.10 | $49K | Direct | Mar 4, 2025 (0d) |
| Feb 3, 2025 | ARQT | ↓ Sell | 12,116 | $12.70 | $154K | Direct | Feb 4, 2025 (1d) |
| Dec 31, 2024 | ARQT | ↓ Sell | 1,691 | $14.00 | $24K | Direct | Dec 31, 2024 (0d) |
| Nov 22, 2024 | ARQT | ↓ Sell | 16,023 | $10.14 | $163K | Direct | Nov 26, 2024 (4d) |
| Nov 15, 2024 | ARQT | ↓ Sell | 69,226 | $10.29 | $713K | Direct | Nov 18, 2024 (3d) |
| Nov 4, 2024 | ARQT | ↓ Sell | 15,441 | $8.68 | $134K | Direct | Nov 5, 2024 (1d) |
| Aug 19, 2024 | ARQT | ↓ Sell | 1,728 | $8.29 | $14K | Direct | Aug 21, 2024 (2d) |
| Aug 2, 2024 | ARQT | ↓ Sell10b5-1 | 13,206 | $9.02 | $119K | Direct | Aug 5, 2024 (3d) |
| May 30, 2024 | ARQT | ↓ Sell | 72,952 | $8.73 | $637K | Direct | May 31, 2024 (1d) |
| May 2, 2024 | ARQT | ↓ Sell10b5-1 | 9,555 | $8.74 | $83K | Direct | May 3, 2024 (1d) |
| Mar 4, 2024 | ARQT | ↓ Sell | 4,782 | $11.12 | $53K | Direct | Mar 6, 2024 (2d) |
| Jan 2, 2024 | ARQT | ↓ Sell | 1,325 | $3.54 | $5K | Direct | Jan 3, 2024 (1d) |
| Aug 21, 2023 | ARQT | ↓ Sell | 1,605 | $7.04 | $11K | Direct | Aug 22, 2023 (1d) |
| Mar 6, 2023 | ARQT | ↓ Sell | 851 | $15.26 | $13K | Direct | Mar 8, 2023 (2d) |
| Mar 2, 2023 | ARQT | ↓ Sell | 1,751 | $15.83 | $28K | Direct | Mar 6, 2023 (4d) |
| Jan 3, 2023 | ARQT | ↓ Sell | 1,475 | $15.01 | $22K | Direct | Jan 4, 2023 (1d) |
| Mar 7, 2022 | ARQT | ↓ Sell | 1,011 | $16.85 | $17K | Direct | Mar 7, 2022 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ARQT insiders
Open-market trades in the last 12 months
About Patrick Burnett's insider trades
Patrick Burnett is EVP, Chief Medical Officer at Arcutis Biotherapeutics (ARQT). Since Mar 7, 2022, Patrick has reported no open-market purchases and 36 sales worth $5.7M on SEC Form 4. In the last 12 months: 11 sales ($1.7M).
6 sales (23% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (10 filings), option exercises (8 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ARQT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.